Companies / Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc.
SYRSCIK 1556263
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Dec 21, 2023 | Akkaraju Srinivas Director | Buy Open-market buy | Common Stock | $4.00M | +905K +102.67% | 1,786,427 | high |
| Jun 28, 2024 | Young Richard A Director | Sell Open-market sale | Common Stock | $178.4K | -35K -81.32% | 8,000 | medium |
| Sep 30, 2022 | Tyson Timothy Director | Buy Open-market buy | Common Stock | $89.2K | +14K +128.06% | 24,932 | medium |
| Sep 11, 2024 | Chee Conley Executive | Buy Open-market buy | Common Stock | $85.4K | +50K +68.96% | 122,504 | medium |
| Sep 12, 2024 | Haas Jason Executive | Buy Open-market buy | Common Stock | $76.0K | +45K +57.25% | 124,552 | medium |
| Sep 10, 2024 | Chee Conley Executive | Buy Open-market buy | Common Stock | $75.3K | +50K +222.18% | 72,504 | medium |
| Apr 1, 2024 | Simonian Nancy A CEO | Other Withheld for taxes | Common Stock | $71.9K | -14K -9.64% | 131,658 | low |
| Apr 1, 2022 | Simonian Nancy A CEO | Other Withheld for taxes | Common Stock | $65.9K | -59K -7.83% | 692,723 | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| SYRS | common | 87184Q107 |
| SYRS | common | 87184Q206 |